Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities (Tables)

v3.19.1
Accrued Liabilities and other Long-Term Liabilities (Tables)
12 Months Ended
Dec. 31, 2018
Payables and Accruals [Abstract]  
Components of Accrued Expenses and Other Long-Term Liabilities
Accrued expenses and other long-term liabilities, excluding National, consisted of the following:
 
 
 
December 31,
 
($ in thousands)
 
2018
 
 
2017
 
Accrued expenses:
 
 
 
 
 
 
 
 
Professional fees
 
$
1,434
 
 
$
1,625
 
Salaries, bonuses and related benefits
 
 
5,843
 
 
 
5,279
 
Accrued expenses - related party
 
 
-
 
 
 
95
 
Research and development
 
 
3,805
 
 
 
1,873
 
Research and development - milestones
 
 
200
 
 
 
800
 
Research and development - manufacturing
 
 
826
 
 
 
1,188
 
Research and development - clinical supplies
 
 
160
 
 
 
85
 
Research and development - license maintenance fees
 
 
519
 
 
 
100
 
Dr. Falk Pharma 
settlement
 
 
300
 
 
 
3,059
 
Accrued royalties payable
 
 
1,108
 
 
 
1,411
 
Accrued coupon expense
 
 
838
 
 
 
1,087
 
Other
 
 
1,327
 
 
 
1,030
 
Total accrued expenses
 
$
16,360
 
 
$
17,632
 
 
 
 
 
 
 
 
 
 
Other long-term liabilities:
 
 
 
 
 
 
 
 
Deferred rent and long-term lease abandonment charge
 
 
5,211
 
 
 
4,739
 
Total other long-term liabilities
 
$
5,211
 
 
$
4,739